(NaturalNews) Three days after approving the Eli Lilly and Amylin Pharmaceuticals drug Byetta as a stand-alone treatment for Type 2 diabetes, the FDA announced that the drug has been linked to kidney damage.
"Health care professionals and patients taking Byetta should pay close attention to any signs or symptoms of kidney problems," said Amy Egan of the metabolism and endocrinology products division.
Byetta (known generically as exenatide) was first approved in 2005 for use in conjunction with other
diabetes drugs only if a patient's blood sugar was failing to respond well to primary treatment. In 2007, the
drug was linked to an increased risk of acute pancreatitis, a severe and potentially fatal inflammation of the
pancreas. Symptoms of the condition include severe abdominal pain, sometimes with nausea and vomiting.
Even when the pancreas is unharmed, Byetta may still cause nausea, diarrhea and vomiting. The latter two conditions may place stress on the
kidneys.
"It is thought that the main reason nausea occurs is the effects of Byetta on the stomach," said Richard Hellman of the University of Missouri-Kansas City School of Medicine. "If someone starts vomiting, they can lower the volume of fluid in their body. If it gets to dangerously low levels, their kidneys could be damaged and
kidney failure could take place."
Although diabetes itself is a major cause of kidney
failure, FDA reports show that among the 80 percent of
patients who stopped taking Byetta after kidney
symptoms emerged, 50 percent recovered.
The
FDA now recommends that Byetta patients be carefully monitored for signs of kidney dysfunction, and that the drug be used cautiously in those with mild or moderate kidney impairment. The drug should not be used in patients with severe kidney failure.
"Before any patient takes Byetta, they should ask their physician whether they have decreased function of their kidneys and whether their kidneys are functioning well enough that taking Byetta would not be hazardous to their
health," Hellman said.
Sources for this story include:
www.reuters.com; www.cnn.com.
Have comments on this article? Post them here:
people have commented on this article.
Email this article to a friend
Share this article on: 
Now Available from 
